Inactive Instrument

Highlights Diamyd Medical AB (publ) Nasdaq Stockholm

Equities

SE0005162880

Highlights

Unlock all the news: Be the first to know and act before the market!

Diamyd Medical AB Updates on the Registrational Phase 3 Trial	05-16	CI
Diamyd Medical Raises SEK57 Million in Rights Issue	04-18	MT
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	04-12	CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	03-27	CI
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA	02-29	CI
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production	01-24	CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023	01-24	CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024	01-04	CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea	12-06	CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial	11-07	MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial	11-07	CI
Diamyd Medical AB Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset	26/10/23	CI
Diamyd Medical AB Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection	20/10/23	CI
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	11/10/23	CI
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2023	11/10/23	CI
Diamyd Medical AB Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US	05/09/23	CI
Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	28/06/23	CI
Diamyd Medical AB Announces Topline Results from Remygen Trial in Individuals with Long-Term Type 1 Diabetes	10/05/23	CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	05/04/23	CI
Diamyd Medical AB Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes	04/04/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Diamyd Medical AB (publ) Nasdaq Stockholm

Equities

SE0005162880

Highlights

Filters